Mannatech, Incorporated — 2012 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2012, compared with fiscal 2011. This is an annual filing, not a standalone fourth-quarter report; the supplied text does not provide a complete quarterly financial comparison.
Business context
Mannatech develops and sells nutritional supplements, skin-care and weight-management products through independent associates and members in an international network-marketing business. It reports one operating segment. At year-end, approximately 229,000 associates and members had purchased products during the prior 12 months. The company began shipping to Ukraine and Hong Kong in late 2012 and planned formal launches there in 2013.
Financial results and liquidity
| Metric | 2012 | 2011 |
|---|---|---|
| Net sales | $173.4 million | $200.7 million |
| Gross profit / margin | $138.8 million / 80.0% | $162.2 million / 80.9% |
| Operating loss / margin | $1.0 million / 0.6% | $16.9 million / 8.4% |
| Net loss / loss per share | $1.4 million / $0.52 | $20.7 million / $7.80 |
| Cash from operating activities | Used $1.2 million | Used $2.9 million |
Revenue fell 13.6%. Cost reductions substantially narrowed operating and net losses, but the company remained loss-making and used cash in operations. Gross margin slipped 0.9 percentage point, primarily reflecting lower sales and higher product costs. Selling and administrative expense declined 22.3% to $37.2 million; total operating expenses declined 21.9% to $139.8 million.
Year-end cash and cash equivalents were $14.4 million, down from $18.1 million. Working capital was $11.1 million, compared with $11.9 million. Total assets were $47.6 million and shareholders’ equity was $20.2 million. The company reported capital-lease obligations of $1.7 million ($0.8 million current); it said it generally funded operations without long-term debt. Restricted cash totaled approximately $5.3 million, including long-term restricted cash.
Cash used in investing activities was $0.6 million and cash used in financing activities was $1.1 million, principally lease repayments. Management expected operating cash flow in 2013 to be sufficient for current operations, while acknowledging that this depended on reversing declining sales and/or further cost reductions.
Changes versus 2011
- Sales declined in all regions: North America fell 15.1% to $86.5 million, Asia/Pacific fell 13.3% to $70.6 million, and EMEA fell 6.3% to $16.3 million. Currency movements reduced 2012 sales by an estimated $2.1 million.
- Product sales declined 9.2%; pack sales fell 46.5% to $11.4 million. Orders decreased 16.7%, while average order value rose 9.6% to $172, partially offsetting lower order volume.
- New active associates and members increased 26% to approximately 97,000, but continuing active purchasers fell 13% to approximately 132,000. The overall active base remained about 229,000.
- Core Ambrotose products generated $78.4 million, or 45.2% of sales, versus $82.4 million, or 41.0%, in 2011—remaining a significant product concentration.
- Management attributed lower expenses to ongoing cost reductions, lower payroll and other operating costs, and reduced depreciation after the company’s enterprise system completed depreciation. The company outsourced U.S. and EMEA warehousing and distribution during 2012.
Outlook, risks and unusual items
- Management said it expected the quarterly improvement in operating results to continue into 2013 and targeted full-year profitability, positive cash flow and a reversal of the sales decline. These are management expectations, not quantified revenue or earnings guidance. Plans included new-market launches, changes to associate compensation and further efficiency measures.
- Key business risks include declining sales and retention of continuing associates, dependence on network-marketing leaders, competition, regulatory scrutiny of supplements and associate claims, foreign-exchange exposure, and reliance on third-party suppliers and manufacturers. Advanced Ambrotose alone contributed 38.2% of 2012 sales.
- The company reported no hedging or derivative activity. Foreign-currency translation and transaction movements affected reported results; transaction gains were approximately $0.7 million in 2012 versus losses of $1.5 million in 2011.
- A favorable $0.8 million adjustment to the post-employment royalty liability reduced 2012 operating costs. A $2.6 million Marinova settlement payment was made in 2012 and recorded in the 2011 financial statements. A separate product-liability case settled for $200,000, of which $79,000 was covered by insurance.
- The IRS had proposed a $8.5 million tax deficiency plus $1.5 million in penalties for tax years 2005–2009; the company disputed the proposed adjustments. At year-end, it recorded $3.0 million of uncertain tax positions. Tax audits and other disputes could adversely affect cash or results.
- The company completed a 1-for-10 reverse stock split in January 2012. Its quarterly dividend, suspended in 2009, remained suspended. Management reported effective disclosure controls and effective internal control over financial reporting; the independent auditor did not issue an opinion on internal-control effectiveness.
Important facts for investors to verify
- Whether sales and order volumes stabilize, particularly given the decline in continuing active purchasers and the large share of sales from Ambrotose products.
- Whether cost reductions and planned market launches deliver sustained full-year profitability and positive operating cash flow in 2013.
- The status and potential cash impact of the IRS examination, uncertain tax positions, and other legal or regulatory matters.
- Cash availability after considering restricted cash, lease and purchase commitments, and any need for additional financing.
- Execution and cost effects of outsourced logistics and the planned Hong Kong and Ukraine operations.